Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Small Intestine Cancer: early-phase trial registry
1 of 12 indexed Small Intestine Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,429 of 28,707 conditions by registered trial count.
12 US clinical trials · 1 currently recruiting · #1,429 of 28,707 conditions by registered trial count
Small Intestine Cancer: 12 US clinical trials tracked, 1 recruiting.
Small Intestine Cancer is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most active sponsor is NYU Langone Health, running 2 of these trials.
Enrollment posture brief
Registry condition small-intestine-cancer
OPEN 1 | RECR 8% | LATE 0 | EARLY 10 | RANK #1429 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Allergic Rhinitis (8% recruiting · 24 trials)
Small Intestine Cancer lists 1 open slots (8% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Small Intestine Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Small Intestine Cancer is recruiting below its size-band peers.
1 of 12 indexed trials (8.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Small Intestine Cancer research.
NYU Langone Health accounts for 2 of 12 trials (16.7%). 9 distinct sponsors appear on at least one study for this condition label.
-
Most Small Intestine Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 53 among the 7 trials that report a genuine target (sentinel values excluded). 5 of those (71.4%) plan for fewer than 100 participants.
-
Small Intestine Cancer research is mostly interventional.
11 interventional and 1 observational studies make up this index (91.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
12 total, page 1 of 1
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Cedars-Sinai Medical Center
NCT04907643
Visceral Lymphatic Mapping Using Isosulfan Blue in Patients With Cancer of the Pancreas, Colon, Stomach, Small Intestine, or Gallbladder
Wake Forest University Health Sciences
NCT00489515
Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma
Memorial Sloan Kettering Cancer Center
NCT00004066
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
Memorial Sloan Kettering Cancer Center
NCT00474994
Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer
NYU Langone Health
NCT00005049
Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer
Vanderbilt-Ingram Cancer Center
NCT00987766
Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
National Cancer Institute (NCI)
NCT00002759
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
NYU Langone Health
NCT00004002
Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus
Boston Medical Center
NCT00006340
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
NCT00005804
VNP40101M in Treating Patients With Advanced or Metastatic Cancer
Vion Pharmaceuticals
NCT00049699
Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis
National Cancer Institute (NCI)
NCT00003368
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Small Intestine Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Small Intestine Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Small Intestine Cancer page
12 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Small Intestine Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- NYU Langone Health sponsors the most Small Intestine Cancer trials on record, review their full trial history before evaluating a specific study. See NYU Langone Health's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Small Intestine Cancer condition card totals 12 registered trials; most-linked intervention gemcitabine hydrochloride; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.